 The purpose of the study is to evaluate the efficacy and safety of Albuferon in combination with ribavirin in interferon IFN alfa treatment-naïve subjects with chronic hepatitis C genotype 1. The study will randomize subjects to 1 of 4 treatment groups including 3 different Albuferon groups or to the active control group, peginterferon alfa-2a PEGASYS, PEG-IFNalfa-2a. All subjects will also receive oral daily ribavirin. 